Tjalf Ziemssen
#138,222
Most Influential Person Now
Researcher
Tjalf Ziemssen's AcademicInfluence.com Rankings
Tjalf Ziemssenmedical Degrees
Medical
#2444
World Rank
#2870
Historical Rank
Neurology
#233
World Rank
#311
Historical Rank
Tjalf Ziemssenphilosophy Degrees
Philosophy
#7085
World Rank
#10244
Historical Rank
Logic
#4160
World Rank
#5418
Historical Rank
Download Badge
Medical Philosophy
Why Is Tjalf Ziemssen Influential?
(Suggest an Edit or Addition)Tjalf Ziemssen's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study (2018) (559)
- Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease (2012) (474)
- Stroke-Induced Immunodepression: Experimental Evidence and Clinical Relevance (2007) (401)
- Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. (2002) (264)
- Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis (2019) (263)
- Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid (2016) (257)
- Non-motor dysfunction in Parkinson's disease. (2007) (207)
- Acute Cerebrovascular Disease in the Young: The Stroke in Young Fabry Patients Study (2013) (199)
- Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study (2013) (194)
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension (2018) (190)
- Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial (2017) (186)
- Glatiramer acetate: mechanisms of action in multiple sclerosis. (2007) (178)
- The Activation Status of Neuroantigen-specific T Cells in the Target Organ Determines the Clinical Outcome of Autoimmune Encephalomyelitis (2004) (177)
- Multiple sclerosis beyond EDSS: depression and fatigue (2009) (165)
- Optimizing treatment success in multiple sclerosis (2015) (154)
- Cardiovascular autonomic dysfunction in Parkinson's disease (2010) (141)
- Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study (2017) (134)
- Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation (2016) (127)
- Psychoneuroimmunology – Cross-talk between the immune and nervous systems (2007) (118)
- A self-sustained loop of inflammation-driven inhibition of beige adipogenesis in obesity (2017) (117)
- Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors (2013) (109)
- The Role of TH17 Cells in Multiple Sclerosis: Therapeutic Implications. (2020) (99)
- Loss of nocturnal blood pressure fall in various extrapyramidal syndromes (2009) (98)
- The norepinephrine system shows information-content specific properties during cognitive control – Evidence from EEG and pupillary responses (2017) (97)
- Molecular biomarkers in multiple sclerosis (2019) (96)
- Therapeutic decisions in multiple sclerosis: moving beyond efficacy. (2013) (93)
- Optimizing therapy early in multiple sclerosis: An evidence-based view. (2015) (91)
- The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). (2005) (89)
- Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world (2017) (85)
- Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. (2016) (85)
- The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System—A Review (2019) (84)
- Use and Acceptance of Electronic Communication by Patients With Multiple Sclerosis: A Multicenter Questionnaire Study (2012) (81)
- Spectral Analysis of Heart Rate Variability: Time Window Matters (2019) (81)
- Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis (2001) (76)
- The importance of collecting structured clinical information on multiple sclerosis (2016) (75)
- Clinical outcome measures in multiple sclerosis: A review. (2020) (72)
- Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS (2019) (72)
- Influence of ECG Sampling Frequency on Spectral Analysis of RR Intervals and Baroreflex Sensitivity Using the EUROBAVAR Data set (2008) (69)
- Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach (2016) (69)
- Review: Patient-reported outcomes in multiple sclerosis care. (2019) (68)
- Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS (2016) (68)
- Demands on response inhibition processes determine modulations of theta band activity in superior frontal areas and correlations with pupillometry – Implications for the norepinephrine system during inhibitory control (2017) (67)
- A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition (2019) (66)
- Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial (2013) (65)
- Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis (2008) (64)
- Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study (2020) (62)
- Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis (2009) (60)
- CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function (2010) (60)
- The norepinephrine system affects specific neurophysiological subprocesses in the modulation of inhibitory control by working memory demands (2017) (59)
- Perceptions on the value of bodily functions in multiple sclerosis (2018) (59)
- Glatiramer acetate: mechanisms of action in multiple sclerosis. (2007) (57)
- Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy (2005) (56)
- Digital Twins for Multiple Sclerosis (2021) (55)
- Therapy satisfaction and adherence in patients with relapsing–remitting multiple sclerosis: the THEPA-MS survey (2016) (54)
- Facilitated defensive coping, silent ischaemia and ECG left-ventricular hypertrophy: the SABPA study (2012) (54)
- Static posturography in aging and Parkinson's disease (2012) (52)
- Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation (2017) (51)
- The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice (2015) (50)
- Autoimmune CD4+ T Cell Memory: Lifelong Persistence of Encephalitogenic T Cell Clones in Healthy Immune Repertoires 1 (2005) (50)
- Symptom management in patients with multiple sclerosis (2011) (50)
- Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. (2018) (49)
- Multiple sclerosis in the real world: A systematic review of fingolimod as a case study. (2017) (49)
- The Effects of Venlafaxine on Autonomic Functions in Healthy Volunteers (2007) (48)
- Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes (2008) (46)
- The sensory channel of presentation alters subjective ratings and autonomic responses toward disgusting stimuli—Blood pressure, heart rate and skin conductance in response to visual, auditory, haptic and olfactory presented disgusting stimuli (2013) (46)
- Review: Brain—immune communication psychoneuroimmunology of multiple sclerosis (2008) (46)
- Effect of BEMER magnetic field therapy on the level of fatigue in patients with multiple sclerosis: a randomized, double-blind controlled trial. (2009) (45)
- Defensive coping facilitates higher blood pressure and early sub-clinical structural vascular disease via alterations in heart rate variability: the SABPA study. (2013) (45)
- Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients (2013) (44)
- Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper) (2021) (44)
- International consensus on quality standards for brain health-focused care in multiple sclerosis (2018) (44)
- Comprehensive autonomic assessment does not differentiate between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy (2009) (44)
- Time- and frequency-domain parameters of heart rate variability and sympathetic skin response in Parkinson’s disease (2015) (44)
- A New Line Immunoassay for the Multiparametric Detection of Antiganglioside Autoantibodies in Patients with Autoimmune Peripheral Neuropathies (2007) (43)
- Natalizumab during pregnancy and lactation (2018) (43)
- Multiple sclerosis and the autonomic nervous system (2006) (42)
- Multiple sclerosis registries in Europe - An updated mapping survey. (2019) (41)
- Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes (2010) (41)
- Considerations on discontinuing natalizumab for the treatment of multiple sclerosis (2010) (41)
- New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies (2016) (41)
- Valsalva manoeuvre in patients with different Parkinsonian disorders (2009) (40)
- The norepinephrine system and its relevance for multi-component behavior (2017) (40)
- Cortisol Awakening Response Is Linked to Disease Course and Progression in Multiple Sclerosis (2013) (39)
- Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis (2020) (39)
- Circadian cortisol, depressive symptoms and neurological impairment in early multiple sclerosis (2011) (39)
- Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System (2016) (38)
- Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential (2018) (38)
- Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis (2017) (38)
- Retinal vessel analysis in hypercholesterolemic patients before and after LDL apheresis. (2009) (38)
- Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential (2018) (38)
- Autonomic dysfunction in different subtypes of multiple system atrophy (2008) (36)
- A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial (2014) (35)
- A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study (2020) (34)
- Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study (2019) (34)
- Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) (2020) (34)
- Accumulation and therapeutic modulation of 6-sulfo LacNAc+ dendritic cells in multiple sclerosis (2014) (32)
- Long‐term peripheral immune cell profiling reveals further targets of oral cladribine in MS (2020) (32)
- Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management (2019) (32)
- Anodal tDCS affects neuromodulatory effects of the norepinephrine system on superior frontal theta activity during response inhibition (2019) (32)
- Autonomic dysfunction in patients with progressive supranuclear palsy (2008) (32)
- The role of phasic norepinephrine modulations during task switching: evidence for specific effects in parietal areas (2018) (31)
- Modern communication technology skills of patients with multiple sclerosis (2013) (28)
- Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients (2018) (28)
- Functional Energetics of CD4+-Cellular Immunity in Monoclonal Antibody-Associated Progressive Multifocal Leukoencephalopathy in Autoimmune Disorders (2011) (28)
- Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study (2009) (28)
- Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™) (2015) (27)
- Hands on Alemtuzumab-experience from clinical practice: whom and how to treat (2016) (27)
- Improving multiple sclerosis management and collecting safety information in the real world: the MSDS3D software approach (2018) (27)
- Regulation of proteins mediating neurodegeneration in experimental autoimmune encephalomyelitis and multiple sclerosis (2009) (27)
- Adult polyglucosan body disease (2003) (27)
- Sudomotor Testing of Diabetes Polyneuropathy (2018) (27)
- Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis (2016) (27)
- Differentiating societal costs of disability worsening in multiple sclerosis (2019) (27)
- Greater cardiovascular reactivity to a cold stimulus is due to higher cold pain perception in black Africans: the Sympathetic Activity and Ambulatory Blood Pressure in Africans (SABPA) study (2012) (26)
- A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views. (2019) (26)
- Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany (2019) (26)
- Seizures associated with zoledronic acid for osteoporosis. (2011) (26)
- Baroreceptor sensitivity, cardiovascular responses and ECG left ventricular hypertrophy in men: The SABPA study (2011) (26)
- Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine (2018) (25)
- Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod (2016) (25)
- Dynamic formation of macular microcysts independent of vitreous traction changes (2015) (25)
- Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis (2005) (25)
- Patients’ preferences for involvement in the decision-making process for treating diabetic retinopathy (2017) (25)
- Treatment of dysautonomia in extrapyramidal disorders (2011) (25)
- Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes (2007) (24)
- Predictors of response to opicinumab in acute optic neuritis (2018) (24)
- Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study (2020) (24)
- Autoantibodies against central nervous system antigens in a subset of B cell–dominant multiple sclerosis patients (2020) (24)
- Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up (2018) (24)
- Graves’ disease after treatment with Alemtuzumab for multiple sclerosis (2002) (24)
- Electronic Health Interventions in the Case of Multiple Sclerosis: From Theory to Practice (2021) (23)
- Electrocardiographic assessments and cardiac events after fingolimod first dose – a comprehensive monitoring study (2017) (23)
- Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS) (2016) (23)
- Trigonometric regressive spectral analysis: an innovative tool for evaluating the autonomic nervous system (2013) (23)
- Trigonometric Regressive Spectral Analysis Reliably Maps Dynamic Changes in Baroreflex Sensitivity and Autonomic Tone: The Effect of Gender and Age (2010) (22)
- Autonomic function and cerebral autoregulation in patients undergoing carotid endarterectomy. (2010) (21)
- Efficacy Analysis of the Anti-LINGO-1 Monoclonal Antibody BIIB033 in Acute Optic Neuritis: the RENEW Trial (P7.202) (2015) (21)
- Determination of Baroreflex Sensitivity during the Modified Oxford Maneuver by Trigonometric Regressive Spectral Analysis (2011) (21)
- Recognition and treatment of autonomic disturbances in Parkinson’s disease (2015) (21)
- A Digital Patient Portal for Patients With Multiple Sclerosis (2020) (21)
- Adrenal medullary dysfunction as a feature of obesity (2017) (20)
- Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis (2020) (20)
- Improving patient–physician dialog: commentary on the results of the MS Choices survey (2012) (20)
- Long-term effects of Bio-Electromagnetic-Energy Regulation therapy on fatigue in patients with multiple sclerosis. (2011) (20)
- QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients (2016) (19)
- Lipoprotein apheresis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells. (2013) (19)
- The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study (2020) (19)
- Effects of Acute and Chronic Stress on the L-Arginine Nitric Oxide Pathway in Black and White South Africans: The Sympathetic Activity and Ambulatory Blood Pressure in Africans Study (2013) (19)
- Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial (2021) (19)
- Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria? (2018) (19)
- Education Research: Cognitive performance is preserved in sleep-deprived neurology residents (2009) (19)
- Time matters – Acute stress response and glucocorticoid sensitivity in early multiple sclerosis (2014) (19)
- How minimal variations in neuronal cytoskeletal integrity modulate cognitive control (2019) (19)
- On the interrelation of 1/f neural noise and norepinephrine system activity during motor response inhibition. (2019) (19)
- Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL (2017) (18)
- Exploring individual multiple sclerosis lesion volume change over time: Development of an algorithm for the analyses of longitudinal quantitative MRI measures (2018) (18)
- [Multiple sclerosis management system 3D. Moving from documentation towards management of patients]. (2012) (18)
- The effects of lorazepam on skin conductance responses to aversive stimuli in healthy subjects (2007) (18)
- Autonomic responses to stress in Black versus Caucasian Africans: the SABPA study. (2012) (18)
- Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS (2017) (17)
- Treatment optimization in multiple sclerosis: how do we apply emerging evidence? (2017) (17)
- Immunoadsorption with regenerating systems in neurological disorders --A single center experience. (2015) (17)
- Management of fingolimod in clinical practice (2013) (17)
- Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies (2019) (16)
- Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis (2021) (16)
- Digital Biomarkers in Multiple Sclerosis (2021) (16)
- Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies (2019) (16)
- Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings (2019) (16)
- Attenuated brain-derived neurotrophic factor and hypertrophic remodelling: the SABPA study (2014) (16)
- Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson’s Disease (CAPTURE PD): Protocol for a Multicenter Study (2017) (15)
- Data Collection in Multiple Sclerosis: The MSDS Approach (2020) (15)
- Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ) (2016) (15)
- Balance Testing in Multiple Sclerosis—Improving Neurological Assessment With Static Posturography? (2020) (15)
- Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis. (2004) (15)
- Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts – the CONFIDENCE study protocol (2020) (15)
- Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients – an observational study (2013) (15)
- Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma. (2014) (15)
- P 2 Effect of ocrelizumab on humoral immunity markers in the phase iii, double-blind, double-dummy, IFN β -1a–controlled OPERA I and OPERA II studies (2017) (14)
- Review: Treatment of dysautonomia in extrapyramidal disorders (2010) (14)
- Impedimetric Microfluidic Sensor-in-a-Tube for Label-Free Immune Cell Analysis. (2021) (14)
- Cardiovascular autonomic testing in extrapyramidal disorders (2011) (14)
- [Adherence to neurologic treatment. Lessons from multiple sclerosis]. (2008) (13)
- Immunomodulatory treatments and cognition in MS (2016) (13)
- Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review (2015) (13)
- Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA (2020) (13)
- Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis (2019) (13)
- Fear of falling and falls in people with multiple sclerosis: A literature review. (2020) (13)
- Rapidly progressive course of very late onset multiple sclerosis presenting with Parkinsonism: case report (2011) (13)
- Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis (2017) (13)
- Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA (2017) (12)
- Differential longitudinal changes of neuronal and glial damage markers in anorexia nervosa after partial weight restoration (2021) (12)
- Multi-component relaxation in clinically isolated syndrome: Lesion myelination may predict multiple sclerosis conversion (2018) (12)
- Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children (2021) (12)
- Different responses of the retinal and cutaneous microcirculation to transient dysmetabolic conditions. (2015) (12)
- Autonomic Dysfunction in Wilson's Disease: A Comprehensive Evaluation during a 3-Year Follow Up (2017) (12)
- Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies (2019) (12)
- Pupillary responses to intranasal trigeminal and olfactory stimulation (2009) (12)
- Should We Use Clinical Tools to Identify Disease Progression? (2021) (12)
- [Chronically ill and unemployed? A review on vocational status in multiple sclerosis]. (2013) (12)
- Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs (2021) (11)
- Therapieadhärenz in der neurologischen Praxis (2008) (11)
- 36 Months Pangaea: A 5-Year Non-Interventional Study of Safety, Efficacy and Pharmacoeconomic Data for Fingolimod Patients In Daily Clinical Practice. (2015) (11)
- Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study (2021) (11)
- An Innovative Technique to Assess Spontaneous Baroreflex Sensitivity with Short Data Segments: Multiple Trigonometric Regressive Spectral Analysis (2018) (11)
- Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis (2021) (11)
- Time for change - Evolution of real-world evidence outcome measures in multiple sclerosis exemplified by fingolimod (2015) (11)
- Acute hyperlipidemia but not hyperhomocysteinemia impairs reflex regulation of the cardiovascular system. (2015) (11)
- Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab (2016) (11)
- Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany (2018) (11)
- Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol (2016) (11)
- Defensive active coping facilitates chronic hyperglycaemia and endothelial dysfunction in African men: the SABPA study. (2013) (11)
- Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab. (2019) (11)
- Perspectives of an innovative ophthalmological technology: Optical coherence tomography (OCT) – What should be of interest to the neurologist? (2013) (11)
- To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question (2017) (10)
- Multiple-Sklerose-Dokumentationssystem 3D (2011) (10)
- Pharmacokinetic/Pharmacodynamic Modelling of Venlafaxine (2008) (10)
- Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting (2018) (10)
- Behandlung der Multiplen Sklerose mit Glatiramer-Azetat (2002) (10)
- Effects of the PPARγ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial (2015) (10)
- Dual-Tasking in Multiple Sclerosis – Implications for a Cognitive Screening Instrument (2018) (10)
- [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action]. (2016) (10)
- LDL apheresis improves deranged cardiovagal modulation in hypercholesterolemic patients. (2010) (10)
- A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm (2020) (10)
- The cold hand sign in multiple system atrophy: skin perfusion revisited (2010) (10)
- The Dresden Protocol for Multidimensional Walking Assessment (DMWA) in Clinical Practice (2020) (9)
- Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects (2021) (9)
- Health-Related Quality of Life and the Relationship to Treatment Satisfaction in Patients with Multiple Sclerosis: Insights from a Large Observational Study (2020) (9)
- Relapses in multiple sclerosis reported by patients versus physicians - Insights from a large observational study. (2020) (9)
- Autonome Dysfunktion beim idiopathischen Parkinson-Syndrom und der Multisystematrophie (2006) (9)
- Study Protocol of AMASIA, a Non-Interventional Study to Gain First Insights on SPMS Patients Treated With Siponimod in Clinical Routine. (2020) (9)
- CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study (2021) (9)
- Serum biomarkers of cerebral cellular stress after self-limiting tonic clonic seizures: An exploratory study (2020) (9)
- Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment (2017) (9)
- Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis (2020) (9)
- Patient‐ versus physician‐reported relapses in multiple sclerosis: insights from a large observational study (2020) (9)
- Visual Feedback and Postural Control in Multiple Sclerosis (2020) (9)
- The need for a strategic therapeutic approach: multiple sclerosis in check (2022) (9)
- Cost of illness in multiple sclerosis by disease characteristics – A review of reviews (2021) (9)
- Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations (2022) (9)
- Early central vs. peripheral immunological and neurobiological effects of fingolimod—a longitudinal study (2019) (9)
- Hes3 expression in the adult mouse brain is regulated during demyelination and remyelination (2016) (9)
- ActiGait implantable drop foot stimulator in multiple sclerosis: a new indication. (2017) (8)
- Potential side effect of high-dose corticosteroid relapse treatment: acute generalized exanthematous pustulosis (AGEP) (2009) (8)
- Development of A Screening Tool to Support Identification of Patients With Secondary Progressive Multiple Sclerosis (Spms). (2015) (8)
- Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion (2017) (8)
- Using Machine Learning Algorithms for Identifying Gait Parameters Suitable to Evaluate Subtle Changes in Gait in People with Multiple Sclerosis (2021) (8)
- CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis (2021) (8)
- Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting (2019) (8)
- The transitional phase of multiple sclerosis: The concept of PANGAEA 2.0 evolution study. (2020) (8)
- Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma (2014) (8)
- Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis (2019) (7)
- Evidence That the Anti-LINGO-1 Monoclonal Antibody BIIB033 Protects Against Multifocal Visual Evoked Potential Amplitude Loss in the Fellow Eye of Subjects with Unilateral Acute Optic Neuritis (S49.006) (2015) (7)
- Axon-Reflex-basierte Nervenmessverfahren in der Diagnostik autonomer Neuropathie (2014) (7)
- Confirmed Disability Improvement In Patients With Active Multiple Sclerosis Treated With Fingolimod Versus Brace: A Matched Comparison of Treatments From The Pangaea And Pearl Registry Studies. (2015) (7)
- Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years (2020) (7)
- Remote-Sensoring – neue Optionen des Progressionsmonitorings bei Multipler Sklerose (2019) (7)
- [Treatment of autonomic dysfunction in patients with extrapyramidal disorders]. (2010) (7)
- Cladribine Alters Immune Cell Surface Molecules for Adhesion and Costimulation: Further Insights to the Mode of Action in Multiple Sclerosis (2021) (7)
- Metabolic and Non-Metabolic Peripheral Neuropathy: Is there a Place for Therapeutic Apheresis? (2019) (7)
- Gender disparities in health resource utilization in patients with relapsing–remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients (2020) (7)
- Regular lipoprotein apheresis maintains residual cardiovascular and microvascular function in patients with advanced atherosclerotic disease. (2013) (7)
- Mutually reinforcing effects of genetic variants and interferon-β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients (2019) (7)
- B Cells, T Cells and Inflammatory CSF Biomarkers in Primary Progressive MS and Relapsing MS in the OBOE (Ocrelizumab Biomarker Outcome Evaluation) Trial (1635) (2020) (7)
- Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration (2020) (6)
- Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper) (2021) (6)
- [Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]. (2021) (6)
- Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses (2022) (6)
- Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie (2016) (6)
- 5 years safety of fingolimod in real world: First results from PANGAEA, a non-interventional study of RRMS patients treated with fingolimod, on safety and adherence after 5 years of fingolimod in daily clinical practice (P5.365) (2017) (6)
- The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis (2017) (6)
- Psychoneuroimmunology - psyche and autoimmunity. (2012) (6)
- Brain Atrophy Is Substantially Accelerated in Neurological Wilson's Disease: A Longitudinal Study (2022) (6)
- Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate (2015) (6)
- 36 month PANGAEA: A 5-year non-interventional study of safety, efficacy and pharmacoeconomic data for fingolimod patients in daily clinical practice (P3.251) (2015) (6)
- Antigen-shift in varicella-zoster virus-specific T-cell immunity over the course of Fingolimod-treatment in relapse-remitting multiple sclerosis patients. (2019) (6)
- Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in a Rare Disease (2021) (6)
- How the depth of processing modulates emotional interference – evidence from EEG and pupil diameter data (2019) (6)
- Wandel in aktueller Bewertung neuer Wirkstoffe erfordert Erhebung pharmakoökonomischer Daten: Behandlungszufriedenheit von Fingolimod (Gilenya) im Vergleich zu Erstlinientherapeutika bei Patienten mit Multipler Sklerose (PANGAEA und PEARL) (2012) (6)
- Chances and Challenges of Registry-Based Pharmacovigilance in Multiple Sclerosis: Lessons Learnt from the Implementation of the Multicenter REGIMS Registry (2020) (6)
- Ethnic‐specific Correlations of Visfatin With Circulating Markers of Endothelial Inflammation and Function (2009) (6)
- A possible role of the norepinephrine system during sequential cognitive flexibility – Evidence from EEG and pupil diameter data (2020) (6)
- [Enhancing monitoring of disease progression-remote sensoring in multiple sclerosis]. (2019) (6)
- Improving Digital Patient Care: Lessons Learned from Patient-Reported and Expert-Reported Experience Measures for the Clinical Practice of Multidimensional Walking Assessment (2021) (6)
- Comprehensive proteomic profiling of serum extracellular vesicles in patients with colorectal liver metastases identifies a signature for non-invasive risk stratification and early-response evaluation (2022) (5)
- Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT® Autoinjector: A Prospective Observational Cohort Study (2021) (5)
- A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose—Possible Predictors of Cardiac Outcomes (2020) (5)
- Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease (2014) (5)
- Fatigue and Sleep in Multiple Sclerosis Patients: A Comparison of Self-Report and Performance-Based Measures (2018) (5)
- Insulin is a key determinant of elevated retinal arteriolar flicker response in insulin-resistant individuals (2015) (5)
- Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey (2021) (5)
- Treatment strategies for nonmotor manifestations of Parkinson's disease. (2009) (5)
- [Real-world evidence : Benefits and limitations in multiple sclerosis research]. (2017) (5)
- Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis (2014) (5)
- Metabolomic distinction of microvascular effects of lipoprotein apheresis--a pilot study. (2013) (5)
- Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis. (2019) (5)
- Neurofilament light chain in serum is significantly increased in chorea-acanthocytosis. (2020) (5)
- Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment (2022) (5)
- In vitro modulation of steroid 5α-reductase activity by phospholipases in epithelium and stroma of human benign prostatic hyperplasia (2001) (5)
- Modernes Therapiemanagement zur Verbesserung der Therapie mit Interferon β-1b mit MSDS 3D (2012) (5)
- Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS (2021) (5)
- Therapieziele und Therapiemanagement bei schubförmigremittierender Multipler Sklerose (2015) (5)
- Anwendung von Immunglobulinen bei primären und sekundären Immundefekten und neurologischen Autoimmunerkrankungen (2012) (5)
- CSF and Serum Biomarkers of Cerebral Damage in Autoimmune Epilepsy (2021) (5)
- How to reduce the delay of diagnosing secondary progression in multiple sclerosis (2020) (5)
- Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions (2022) (5)
- Profiles of eHealth Adoption in Persons with Multiple Sclerosis and Their Caregivers (2021) (5)
- Laquinimod in the treatment of relapsing remitting multiple sclerosis (2016) (5)
- Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data (2021) (5)
- Study Design and First Results of a Non-Interventional Registry Study To Establish Long-Term Safety and Pharmaco-Economic Data on Fingolimod (Gilenya(R)) in Multiple Sclerosis Patients in Germany (PANGAEA) (P04.131) (2012) (5)
- [Axon-reflex based nerve fiber function assessment in the detection of autonomic neuropathy]. (2014) (5)
- Treatment strategies for nonmotor manifestations of Parkinson's disease (2009) (5)
- Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients (2021) (5)
- 4 Years PANGAEA: A 5-Year Non-Interventional Study of Safety, Effectiveness and Pharmacoeconomic Data for Fingolimod Patients in Daily Clinical Practice - Effectiveness Update (P3.072) (2016) (4)
- How to Implement Adherence-Promoting Programs in Clinical Practice? A Discrete Choice Experiment on Physicians’ Preferences (2020) (4)
- Mehr als dokumentieren: computerunterstütztes Patientenmanagement (2013) (4)
- Kommentar der Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) zur S2k-Leitlinie Multiple Sklerose (2021) (4)
- Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study (2021) (4)
- PANGAEA: Post-authorization Noninterventional German Safety Study of GilEnyA in relapsing-remitting multiple sclerosis (RRMS) patients: A 24-month interim analysis of a German five-year fingolimod registry study (2014) (4)
- Treatment of multiple sclerosis with glatiramer acetate - new information about its mechanisms of action, pharmacokinetics, adverse effects and clinical studies (2002) (4)
- [Multiple sclerosis. An update with practical guidelines for ophthalmologists]. (2006) (4)
- Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation (2021) (4)
- 6‐sulpho LacNAc+ dendritic cells accumulate in various inflammatory, but not ischaemic conditions of the central nervous system (2016) (4)
- Peripheral nerve field stimulation in medically refractory trigeminal neuralgia attributed to multiple sclerosis. (2020) (4)
- Untersuchung zur Genauigkeit der Abtastung von EKG-Signalen für eine nachfolgende Spektralanalyse kontinuierlich gemessener RR-Intervalle im Schlaflabor (2006) (4)
- Recent perspectives in neurology (2013) (4)
- A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe. (2015) (4)
- [Treatment of multiple sclerosis with glatiramer acetate. Current aspects of mechanisms of action, pharmacokinetics, adverse effect profile and clinical studies]. (2002) (4)
- Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany (2022) (4)
- 18-Month Interim Results of a Registry Study To Establish Long-Term Safety and Pharmaco-Economic Data on Fingolimod (Gilenya®) in Multiple Sclerosis Patients in Germany (PANGAEA) (P01.185) (2013) (4)
- Rationale and design of the prevention of paclitaxel-related neurological side effects with lithium trial – Protocol of a multicenter, randomized, double-blind, placebo- controlled proof-of-concept phase-2 clinical trial (2022) (4)
- Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies (2020) (4)
- Attenuated NOx responses and myocardial ischemia, a possible risk for structural vascular disease in African men: the SABPA study (2014) (4)
- Phospholipase A2 degradation products modulate epithelial and stromal 5α‐reductase activity of human benign prostatic hyperplasia in vitro (2002) (4)
- Properties of lower level processing modulate the actions of the norepinephrine system during response inhibition (2020) (3)
- Multiple Sclerosis Documentation System MSDS3D - Innovative Management of Patients with Multiple Sclerosis (P3.130) (2014) (3)
- On the Reliability of Examining Dual-Tasking Abilities Using a Novel E-Health Device—A Proof of Concept Study in Multiple Sclerosis (2020) (3)
- [Implementation of the National Guidelines for the treatment of Diabetes mellitus type 2 in secondary diabetes centers]. (2017) (3)
- What can we learn from failed clinical trials in multiple sclerosis? (2008) (3)
- Neural and glial damage markers in women after long-term weight-recovery from anorexia nervosa (2021) (3)
- Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis (2021) (3)
- 24-Month Interim Results Of PANGAEA: A 5-Year Registry Study Evaluating Long-Term Safety, Efficacy And Pharmacoeconomic Data Of German Multiple Sclerosis Patients On Fingolimod Therapy (P3.152) (2014) (3)
- Intravitreous bevacizumab and blood pressure: does 'safe' mean 'safe enough'? (2007) (3)
- Response to Hyun J.W. et al. “Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis” (2020) (3)
- Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials (2022) (3)
- Comparison of baroreflex sensitivity estimated from ECG R–R and inter-systolic intervals obtained by finger plethysmography and radial tonometry (2016) (3)
- Wissensstand von Patienten und Gesundheitsberufen über Diabetes-bedingte Augenerkrankungen (Risikofaktoren, Früherkennung und Behandlung) (2018) (3)
- Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety (2022) (3)
- Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions (2021) (3)
- Alemtuzumab Has Similar Efficacy and Safety in Active Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Who Were Treatment-Naive or Who Relapsed on Prior Therapy (P2.209) (2014) (3)
- Effectiveness of Fingolimod Compared with Interferons and Glatiramer Acetate for the Treatment of Multiple Sclerosis: A Matched Comparison of Treatments from the PANGAEA and PEARL Studies (P3.253) (2015) (3)
- Prolonged-Release Fampridine Induces Sustained Clinically Meaningful Improvements in Walking Ability in People with Multiple Sclerosis: Results from the ENHANCE Trial (P6.364) (2017) (3)
- Phase 2 BOLD Extension Study Safety Results for Siponimod (BAF312) in Patients with Relapsing–Remitting Multiple Sclerosis (P01.176) (2013) (3)
- Patientenintegration durch Pfadsysteme (2019) (3)
- Nocturnal blood pressure, 3-methoxy-4-hydroxyphenylglycol and carotid intima-media thickness: The SABPA study. (2013) (3)
- Relation of retinal and hippocampal thickness in patients with amnestic mild cognitive impairment and healthy controls (2021) (3)
- Sustained clinically meaningful improvements in walking ability with prolonged-release fampridine: results from the placebo-controlled ENHANCE study. (2016) (3)
- Innovation in Digital Education: Lessons Learned from the Multiple Sclerosis Management Master’s Program (2021) (3)
- Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC) (2022) (3)
- Serum neurofilament light chain and initial severity of neurological disease predict the early neurological deterioration in Wilson’s disease (2022) (3)
- A role of the norepinephrine system or effort in the interplay of different facets of inhibitory control (2022) (3)
- A Phase 3b/4 Long-Term Study of Alemtuzumab in Patients With Relapsing-Remitting Multiple Sclerosis: TOPAZ Study Design (P7.219) (2015) (3)
- Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a (2016) (2)
- First Dose Effects of Fingolimod: An in-depth Analysis of the first 2500 START Patients (S4.005) (2015) (2)
- The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0 (2021) (2)
- P 1 Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis – analysis of the phase III, double-blind, double-dummy, interferon beta-1a- controlled OPERA I and OPERA II studies (2017) (2)
- [New master's program: multiple sclerosis management]. (2022) (2)
- Der Multiple Sclerosis Health Resource Utilization Survey (2021) (2)
- Comparison of Efficacy and Treatment Satisfaction of Patients on Baseline Therapy or Fingolimod: Results of the Interim Analysis of Two German Registry Studies PANGAEA and PEARL (P7.232) (2014) (2)
- Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity (2023) (2)
- The Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) patient cohort (P4.381) (2018) (2)
- Umsetzung der Nationalen VersorgungsLeitlinie (NVL) zur Therapie des Diabetes mellitus Typ 2 in diabetologischen Schwerpunktpraxen (2017) (2)
- Internationale „Brain Health Initiative“ und Multiple Sklerose (2020) (2)
- MSProDiscuss – Entwicklung eines digitalen Tools zur standardisierten Patientenanamnese, um Progredienz bei Multipler Sklerose zu identifizieren (2021) (2)
- Serum neurofilament light chain levels are associated with stroke severity and functional outcome in patients undergoing endovascular therapy for large vessel occlusion (2021) (2)
- Metabolische Störungen (2008) (2)
- Dem MS-Phänotyp auf der Spur (2019) (2)
- Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study (2022) (2)
- Safety and Tolerability of Anti-LINGO-1 Monoclonal Antibody BIIB033 in Acute Optic Neuritis: the RENEW trial (P7.203) (2015) (2)
- Good Cardiac Safety In Patients With Relapsing Remitting Multiple Sclerosis Upon First Fingolimod Dose (P2.197) (2014) (2)
- Associations of sNfL with clinico‐radiological measures in a large MS population (2022) (2)
- Disease activity during pregnancy and pregnancy outcomes in patients with multiple sclerosis treated with Alemtuzumab – A case series from the German MS and Pregnancy Registry (P1.367) (2017) (2)
- Why Cognitive–Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice (2020) (2)
- B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis (2021) (2)
- Local endothelial dysfunction does not affect global endothelial function. (2015) (2)
- Low rate of conversion from relapsing-remitting MS to secondary progressive MS through 6 years among patients who received alemtuzumab in CARE-MS I and II (2017) (2)
- Automated Analysis of the Two-Minute Walk Test in Clinical Practice Using Accelerometer Data (2021) (2)
- Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod (2017) (2)
- Pangaea 2.0: State Of The Art Multiple Sclerosis Patient Management In Daily Clinical Practice. A New 3-Year Observational Study Of Patients Receiving Fingolimod. (2015) (2)
- Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies (2021) (2)
- Modern Therapy Management for the Improvement of the Therapy with Interferon β-1b with MSDS 3D (2012) (2)
- Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more (2022) (2)
- MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression (2022) (2)
- Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence. (2019) (2)
- [Stress-cardiomyopathy--a psychological phenomenon?]. (2013) (2)
- innovative management of Ms patients on natalizumab using Msds-3d software : P1722 (2012) (2)
- Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis (2018) (2)
- Serum neurofilament indicates that DBS surgery can cause neuronal damage whereas stimulation itself does not (2022) (2)
- RENEWED: Long-Term Electrophysiological and Clinical Outcomes in Participants Previously Enrolled in the Opicinumab Phase 2 Study RENEW (1599) (2020) (2)
- The Multiple Sclerosis Data Alliance Catalogue: Enabling Web-Based Discovery of Metadata from Real-World Multiple Sclerosis Data Sources. (2021) (2)
- Integration of ocrelizumab safety data from the German study CONFIDENCE into the global post-marketing safety studies MANUSCRIPT and VERISMO (2018) (2)
- Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients: A Double-Center, Randomized Controlled Pilot Trial (2015) (1)
- Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis (2022) (1)
- Prolonged-release fampridine demonstrates rapid and sustained clinically meaningful improvements in walking ability over 24 weeks : MSWS-12 responders in the ENHANCE study (2017) (1)
- Anodal tDCS affects neuromodulatory effects of the norepinephrine system on superior frontal theta activity during response inhibition (2019) (1)
- Response to: S. Sega-Jazbec et al.: "Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis" Multiple Sclerosis and Related Disorders 2017. (2017) (1)
- Analysis of Efficacy by Multifocal Visual Evoked Potentials in Subjects Treated with the Anti-LINGO-1 Monoclonal Antibody BIIB033 in Acute Optic Neuritis: the RENEW Trial (P7.208) (2015) (1)
- Multicomponent Relaxation in Clinically Isolated Syndrome (2012) (1)
- OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany (2022) (1)
- Baseline Characteristics And Interim Analysis Results Of The Fingolimod Cohort In The World-Wide Post-Approval Safety Program (PASSAGE) (P2.202) (2014) (1)
- [Interdisciplinary communication: ophthalmologists' letters to practices specializing in diabetic patients]. (2020) (1)
- RWD126 Introducing the German MSDS-AOK PLUS Database: Linkage of Administrative Claims Data and a Patient Registry for Advanced RWE Capabilities in Multiple Sclerosis (2022) (1)
- Neuroborreliosis during natalizumab treatment in multiple sclerosis (2013) (1)
- Early Mobility Impairment: Bridging the Communication Gap between People with Multiple Sclerosis and Their Healthcare Providers (P03.221) (2013) (1)
- Delayed retinal vein recovery responses indicate both non-adaptation to stress as well as increased risk for stroke: the SABPA study. (2020) (1)
- Efficacy for remyelination and safety of anti-lingo-1 monoclonal antibody (biib033) in acute optic neuritis: results from the renew study (2015) (1)
- Psychometric Analyses to Inform Item Reduction and Evaluate Sensitivity of the Early Mobility Impairment Questionnaire for Multiple Sclerosis. (2014) (1)
- Efficacy of prolonged-release fampridine vs placebo on walking ability, dynamic and static balance and quality-of-life: an integrated analysis of MOBILE and ENHANCE (2018) (1)
- Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany (2022) (1)
- Der Patient als Experte (2020) (1)
- MS-Monitoring mit molekularen Biomarkern - wo stehen wir? (2021) (1)
- Schübe und Progression der MS klinisch beurteilen (2020) (1)
- Die Zukunft der Biomarker ist digital (2021) (1)
- Interdisziplinäre Kommunikation: Augenarztbriefe an diabetologische Schwerpunktpraxen (DSP) (2020) (1)
- Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study (2022) (1)
- 4 Years Safety of Fingolimod in Real World: PANGAEA, a Non-Interventional Study of Safety, Effectiveness and Pharmacoeconomic Data for Fingolimod Patients in Daily Clinical Practice (P2.077) (2016) (1)
- Monitoring der subklinischen MS-Krankheitsaktivität (2020) (1)
- The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study (Preprint) (2020) (1)
- Safety and Tolerability of Escalating Doses of Laquinimod, an Oral Immunomodulatory Agent in Development for Treatment of Relapsing-Remitting Multiple Sclerosis (P2.205) (2014) (1)
- Interim Results of the PANGAEA and PEARL Studies, Comparing Treatment Satisfaction and Pharmaco-Economic Data of Fingolimod (Gilenya®) and First-Line Therapies in Multiple Sclerosis Patients in Germany (P03.220) (2013) (1)
- "Miss alles, was sich messen lässt" (2020) (1)
- No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis (2020) (1)
- Quality of life improves with alemtuzumab over 6 years even in patients with relapsing-remitting multiple sclerosis who developed thyroid adverse events (2018) (1)
- Immunomodulatory Treatment Strategies Differently Affect Dendritic Cells in Multiple Sclerosis Patients (S11.006) (2013) (1)
- Neuer Masterstudiengang: Multiple Sklerose Management (2022) (1)
- Die Relevanz des Multitaskings (2021) (1)
- RWD24 Assessing the Performance of Propensity Score Methods in Balancing Unobservable Confounders: Evidence From Linked Data in Multiple Sclerosis (2022) (1)
- Evozierte Potenziale - noch up to date? (2020) (1)
- Master im Multiple-Sklerose-Management (2019) (1)
- Morbus Parkinson — Gehirnerkrankung oder Ganzkörpererkrankung? (2003) (1)
- Real-world-Evidenz (2017) (1)
- Was die Schritte verraten (2020) (1)
- Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks (2018) (1)
- Baseline characteristics of patients enrolled in CONCERTO - a study of 0.6 and 1.2 mg/day oral laquinimod for relapsing-remitting multiple sclerosis (P7.216) (2015) (1)
- Die Neurodegeneration an den Augen ablesen (2021) (1)
- Ein Jahr Alemtuzumab – was haben wir in der Praxis gelernt? Experten-Erfahrungsaustausch zur Therapie der Multiplen Sklerose (2015) (1)
- Chronisch krank und ohne Arbeit? Eine aktuelle Analyse zur Erwerbstätigkeit bei Multipler Sklerose (2013) (1)
- Wie messe ich das Unsichtbare? (2021) (1)
- Das Herz in der Tintenfischfalle (2013) (1)
- Time-On-Task Effects on Working Memory Gating Processes—A Role of Theta Synchronization and the Norepinephrine System (2022) (1)
- Kipptischuntersuchung – Schritt für Schritt (2019) (1)
- Time Off From Work: a Matched Comparison of Fingolimod and BRACE in Patients with Multiple Sclerosis from the PANGAEA and PEARL Studies (P7.019) (2015) (1)
- Autonome Small-Fiber-Neuropathien (2019) (1)
- Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey (Preprint) (2021) (1)
- Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial (2014) (1)
- 4 Years PANGAEA: Long Term Data on Effectiveness and Safety from Patients on Natalizumab Switching to Fingolimod in Real World (P6.188) (2016) (1)
- Editorial: Cognitive Disorders in Neuroimmunological Diseases (2020) (1)
- Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients (2022) (1)
- Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab (2022) (1)
- Digital Innovation in Multiple Sclerosis Management (2021) (1)
- Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in an Ultra-Rare Disease (2021) (1)
- Safety and Efficacy of Siponimod (BAF312) in Patients with Relapsing-remitting Multiple Sclerosis: Results from Dose-blinded Extension Phase of BOLD Study (P3.151) (2014) (1)
- Design of a Non-interventional Study to Establish Effectiveness, Quality of Life, Cognition, Health-Related and Work Capacity Data on Alemtuzumab in Multiple Sclerosis Patients in Germany (TREAT-MS) (P7.281) (2015) (1)
- FastCAT Accelerates Absolute Quantification of Proteins Using Multiple Short Nonpurified Chimeric Standards (2021) (1)
- Dissonance in Music Impairs Spatial Gait Parameters in Patients with Parkinson's Disease. (2020) (1)
- Letter to the editor on the paper: “The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing” (2018) (1)
- RWD58 Coding of Multiple Sclerosis Subtypes in German Administrative Claims Data: A Validation Study Using the MSDS-AOK PLUS Linked Database (2022) (1)
- Kapitel 28 – MS-Dokumentation, MS-Register und MS-Management (2015) (0)
- PND148 - DEVELOPMENT OF A DIGITAL APP AND INNOVATIVE RECRUITMENT FOR AN INTERNATIONAL REAL-WORLD OBSERVATIONAL STUDY IN CHARCOT MARIE TOOTH DISEASE (2018) (0)
- Dendritic cells are specifically affected by different immunomodulatory treatment strategies in multiple sclerosis (2014) (0)
- Multi-Component Relaxation In Untreated Relapsing-Remitting Multiple Sclerosis (2011) (0)
- AMA-VACC: Clinical trial assessing the immune response to SARS-CoV-2 mRNA vaccines and booster vaccination in siponimod treated patients with secondary progressive multiple sclerosis (P12-3.004) (2023) (0)
- On the reliability of examining dual-tasking abilities using a novel e-Health device – a proof of concept study in Multiple Sclerosis (2020) (0)
- PANGAEA 2.0: State of the Art Multiple Sclerosis Patient Management in Daily Clinical Practice. A 3-Year Observational Study of Patients Receiving Fingolimod (P3.031) (2016) (0)
- Effects of Pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial (2013) (0)
- Stress and neurovascular coupling: A red flag? The SABPA Study (2019) (0)
- 928 DEFENSIVE ACTIVE COPING FACILITATES CHRONIC HYPERGLYCEMIA AND EARLY VASCULAR STRUCTURAL CHANGES IN AFRICAN MEN: THE SYMPATHETIC ACTIVITY AND AMBULATORY BLOOD PRESSURE IN AFRICANS (SABPA) STUDY (2012) (0)
- Subthalamic nucleus stimulation and levodopa modulate cardiovascular autonomic function in Parkinson’s disease (2017) (0)
- Data Resource Profile: The Multiple Sclerosis Documentation System 3D and AOK PLUS Linked Database (MSDS-AOK PLUS) (2023) (0)
- Heart rate variability and sympathetic skin response in Parkinson's disease: Baseline assessment of the MODEP study (2013) (0)
- Experience with Serious Cutaneous Events in the DECIDE Study (P2.083) (2016) (0)
- P23 Assessing the Long-term Outcomes of Ocrelizumab Treatment in Germany – CONFIDENCE Baseline Characteristics (2020) (0)
- Improved Gastrointestinal Tolerability Profile with Diroximel Fumarate Compared to Dimethyl Fumarate in Relapsing MS Patients (994) (2020) (0)
- PRO138 PRODUCTIVITY LOSSES IN PEOPLE WITH CHARCOT-MARIE-TOOTH DISEASE IN THE EU AND US: INTERIM RESULTS FROM AN INTERNATIONAL DIGITAL REAL-WORLD EVIDENCE STUDY (2019) (0)
- 191 MOBILE/ENHANCE integrated efficacy analysis of PR-fampridine (2019) (0)
- Serum neurofilament light concentrations are associated with cortical thinning in anorexia nervosa. (2023) (0)
- Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany. (2021) (0)
- Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis (2020) (0)
- Effect of early initiation or switch to fingolimod on relapse outcomes in patients with relapsing-remitting multiple sclerosis: Pooled analysis from Phase 3 and Real-World studies (2017) (0)
- Real-world data on eculizumab treatment in NMOSD: high efficacy and potential challenges (P13-5.017) (2023) (0)
- Subthalamic nucleus stimulation and levodopa modulate cardiovascular autonomic function in Parkinson’s disease (2017) (0)
- STRESS APPRAISAL A HEALTH PROMOTER? EVIDENCE FOR DESENSITIZATION OF HEART RATE VARIABILITY NEURAL CONTROL: THE SYMPATHETIC ACTIVITY AND AMBULATORY BLOOD PRESSURE IN AFRICANS (SABPA) STUDY (2014) (0)
- the first three years after diagnosis Neurological disability , psychological distress , and health-related quality of life in MS patients within (2009) (0)
- Accumulationandtherapeuticmodulation of 6-sulfo LacNAc 1 dendritic cells in multiple sclerosis (2014) (0)
- Creating a consensus evaluation and expert opinion reporting platform for brain MRI in Multiple Sclerosis with higher increased risk of Progressive Multifocal Leukoencephalopathy. (2016) (0)
- Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies (2023) (0)
- PRO47 PATIENT-REPORTED REAL-WORLD CARE STANDARDS FOR CHARCOT-MARIE-TOOTH DISEASE IN THE UK AND US ASSESSED USING A DIGITAL 'BRING YOUR OWN DEVICE' PLATFORM (2019) (0)
- Comparison of Time to Clinically Meaningful Improvement in Neuro-QOL in Patients Treated with Natalizumab Versus Ocrelizumab (2022) (0)
- Baseline Characteristics of Patients in the PANGAEA Study (P3.030) (2016) (0)
- Tracking the immune response to SARS-CoV-2 mRNA booster vaccination in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS clinical trial) (P2-3.016) (2023) (0)
- Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis (2021) (0)
- P1.18 Frequent nocturnal blood pressure dysregulation in various extrapyramidal syndromes (2009) (0)
- Abstract WP344: Vascular Unloading Technique for Continuous Non-invasive Blood Pressure Monitoring After Intravenous Thrombolysis in Acute Ischemic Stroke: Interim Analysis of a Prospective Method Comparison Study (2016) (0)
- Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis (2020) (0)
- PRO93 DEMOGRAPHICS AND TREATMENT PATTERNS FOR CHARCOT-MARIE-TOOTH DISEASE IN THE EU AND US: INTERIM RESULTS FROM AN INTERNATIONAL DIGITAL REAL-WORLD STUDY (2019) (0)
- A New Complementary Video Head Impulse Test Paradigm to Elicit Anti-Compensatory Saccades as an Indicator of Peripheral Vestibular Function (2016) (0)
- Immunomodulatory therapy in 5798 relapsing-remitting multiple sclerosis (RRMS) patients over time under special consideration of switching to oral DMD: A retrospective data analysis (2017) (0)
- Pharmacokinetics and -Dynamics of Natalizumab after Cessation and at Different Dosing Intervals (P06.167) (2012) (0)
- Driving time-based identification of gaps in specialised care coverage: An example of neuroinflammatory diseases in Germany (2023) (0)
- Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart® Injector: Results of the Prospective Cohort Study REBIFLECT (2022) (0)
- Immunological Effects by Longterm Fingolimod Therapy in MS (P05.158) (2013) (0)
- Monitoring Free and Cell-Bound Natalizumab in CSF and Blood in Natalizumab-Treated MS Patients (P02.071) (2012) (0)
- Disability, Health Status and Estimation of Treatment Effectiveness with Versus without an MS Relapse (PEARL Study) (P3.259) (2015) (0)
- Reader Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use (2022) (0)
- Posters on Display (2019) (0)
- Abstract 395: Lipoprotein Apheresis of Hypercholesterolemic Patients Mediates Vasoprotective Gene Expression in Human Endothelial Cells (2013) (0)
- Short-term and Long-term Effects of Fingolimod on the Cardiovascular Autonomic Nervous System (P2.196) (2014) (0)
- Economic Cost of an MS Relapse (PEARL Study) (P1.139) (2015) (0)
- Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA (Preprint) (2020) (0)
- 290 GREATER CARDIOVASCULAR REACTIVITY TO A COLD PRESSOR TEST IS DUE TO HIGHER COLD PAIN PERCEPTION IN BLACK AFRICANS: THE SABPA STUDY (2012) (0)
- The RADIANCE and SUNBEAM phase 3 studies of ozanimod in relapsing multiple sclerosis: study design and baseline characteristics (P6.344) (2017) (0)
- Detection of Fall Risk in Multiple Sclerosis by Gait Analysis—An Innovative Approach Using Feature Selection Ensemble and Machine Learning Algorithms (2022) (0)
- Efficacy of Alemtuzumab Retreatment in Patients Who Experienced Disease Activity after the Initial Two Courses: Results from the CARE-MS II Extension (2018) (0)
- Effects of Multiple Sclerosis Therapies on the Gut Immune System (P6.191) (2016) (0)
- SlanDCs as Crucial Target of the MS-Immunmodulator Laquinimod (P05.156) (2013) (0)
- Development of an EAE model for histopathological subtype II of MS: role of humeral immune system (2005) (0)
- Challenges in Grading of Diabetic Retinopathy using Non-mydriatic Wide-field Imaging (2017) (0)
- Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS (2017) (0)
- The influence of the COVID-19 pandemic on the prescription of multiple sclerosis medication in Germany (2022) (0)
- Transparent Quality Optimization for Machine Learning-Based Regression in Neurology (2022) (0)
- A Qualitative Assessment of Key Symptoms Associated with the Progression from RRMS to SPMS by Physicians and Patients (P2.156) (2016) (0)
- Early central vs. peripheral immunological and neurobiological effects of fingolimod—a longitudinal study (2019) (0)
- Do persons with diabetes want to decide on their own when treating diabetic retinopathy? The intended role of the ophthalmologist - results of the DiabCheckOCT+ Study. (2015) (0)
- PANGAEA: 5 years effectiveness of fingolimod in daily clinical practice (P6.393) (2018) (0)
- Comprehensive proteomic profiling of serum extracellular vesicles in patients with colorectal liver metastases identifies a signature for non-invasive risk stratification and early-response evaluation (2022) (0)
- Serological Biomarker Profiles of Neurofilament Light Chain in Children and Adolescents with Spinal Muscular Atrophy and Healthy Controls (2021) (0)
- Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation (2017) (0)
- Exploring in vivo lesion myelination dynamics: Longitudinal Myelin Water Imaging in early Multiple Sclerosis (2022) (0)
- Differential Effects of Natalizumab and Fingolimod on the Innate Immune System of MS Patients (P04.125) (2012) (0)
- PP.41.04: DEPRESSION AND REDUCED PERFUSION - THE EYES TELL IT ALL: THE SYMPATHETIC ACTIVITY AND AMBULATORY BLOOD PRESSURE (SABPA) STUDY (2015) (0)
- Intracellular production of brain-derived neurotropbic factor (BDNF) in T-cells of healthy controls, untreated MS patients and interferon-beta treated MS patients before and after stimulation with PMA/ionomycin or interferon-beta (2004) (0)
- Differential Immunological Changes in Peripheral and CNS Compartments during Fingolimod Therapy in MS (P02.087) (2012) (0)
- Pharmacokinetics of Laquinimod, an Oral Immunomodulatory Agent in Development for The Treatment of Relapsing-Remitting Multiple Sclerosis (P7.237) (2014) (0)
- Prevalence of diabetic retinopathy in dependence on the steps of Diabetes Management Guidelines (2016) (0)
- P.5.b.003 Anxiety and depression in patients with multiple sclerosis: results of the MS Caregiver Burden study (2012) (0)
- [MSProDiscuss - Development of a digital anamnesis tool to identify disease progression in multiple sclerosis]. (2021) (0)
- Greater cardiovascular reactivity to a cold pressor test is due to higher cold pain perception in Black Africans : the SABPA study Short title : cold pain and cardiovascular regulation Authors and Affiliations (2014) (0)
- No Association Between Lymphocyte Pharmacodynamics and Disability Following Alemtuzumab Treatment in patients With Relapsing-Remitting Multiple Sclerosis (2019) (0)
- Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients (2022) (0)
- Front & Back Matter (2020) (0)
- Countermovement Jumps Detect Subtle Motor Deficits in People with Multiple Sclerosis below the Clinical Threshold (2023) (0)
- Secondary Progressive Multiple Sclerosis (2022) (0)
- Long-term Effect of Ofatumumab Treatment on Serum Neurofilament Light Chain Levels and NEDA-3 Status in Patients With RMS: Results From ASCLEPIOS I/II and ALITHIOS (P6-3.013) (2023) (0)
- Disturbances of the Autonomic Nervous System in PD Patients (2005) (0)
- New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies (2016) (0)
- Are Embodied Conversational Agents effective Tools for collecting Patient-reported Outcome Measures? - Towards a novel Approach in Multiple Sclerosis Care (2022) (0)
- Correction to: Differentiating societal costs of disability worsening in multiple sclerosis (2020) (0)
- Secondary Progressive Multiple Sclerosis A Review of Clinical Characteristics, De fi nition, Prognostic Tools, and Disease-Modifying Therapies (0)
- Long-term Effects of Electromagnetic-field Therapy on Fatigue in Patients With Multiple Sclerosis (2011) (0)
- Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE (2022) (0)
- Utilization, Effectiveness and Safety of Daclizumab Beta in the Real World: Interim Analysis of the Observational ZEUS Study in Germany (P6.384) (2018) (0)
- Multiple Sklerose (2006) (0)
- Pharmacoeconomic and Clinical Characteristics in Patients with Multiple Sclerosis Treated with Disease Modifying Therapies: PEARL - 24 Months Results (P4.148) (2014) (0)
- PRO37 HEALTHCARE RESOURCE USE IN CHARCOT-MARIE-TOOTH DISEASE IN THE EU AND US: INTERIM RESULTS FROM AN INTERNATIONAL DIGITAL REAL-WORLD STUDY (2019) (0)
- Limitations of Retinal Thickness Analysis in Cross-Sectional Data (2016) (0)
- PMU81 - PHYSICIANS' PREFERENCES WITH RESPECT TO ADHERENCE PROGRAMS: A DISCRETE CHOICE EXPERIMENT (2018) (0)
- The role of phasic norepinephrine modulations during task switching: evidence for specific effects in parietal areas (2017) (0)
- AMASIA study: Real world insights on the impact of early siponimod treatment on SPMS patients in Germany (P8-3.013) (2023) (0)
- Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" Multiple Sclerosis and Related Disorders 2017. (2018) (0)
- Knowledge about diabetic retinopathy: Patients vs. Professionals (diabetologists, diabetes advisors) (2015) (0)
- Cognitive Impairment and MRI-based Disease Progression in MS PATHS: Variable Susceptibility Across the Lifespan (1334) (2020) (0)
- Final results of the PANGAEA 2.0 study: Treatment benefits of fingolimod for active RRMS patients switching from other DMTs (P6-3.009) (2023) (0)
- Efficacy of Alemtuzumab in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Received Retreatment Due to Disease Activity After the Initial Two Courses: Results From the CARE-MS II Extension (P6.363) (2018) (0)
- PO111 Daclizumab efficacy in highly active rrms: select/decide (2017) (0)
- TRUST - A Study to Evaluate an Integrated Approach for Optimized Patient Management in Multiple Sclerosis Patients Treated with Natalizumab - First Analysis of Baseline Data (P2.147) (2016) (0)
- Reader response: Pregnancy decision making in women with multiple sclerosis treated with natalizumab: I: Fetal risk II: Maternal risk (2018) (0)
- Pharmacodynamic Effect of Intravitreous Bevacizumab on the Flicker–Response in Retinal Arterioles (2006) (0)
- Brain structure and neurocognitive function in two professional mountaineers during 35 days of severe normobaric hypoxia (2022) (0)
- Phospholipids modulates 5alpha-reductase activity in epithelium and stroma of human benign prostatic hyperplasia in vitro (1998) (0)
- Auricular transcutaneous vagus nerve stimulation specifically enhances working memory maintenance – a system neurophysiological study (2023) (0)
- Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis (2023) (0)
- ILLUMINATE: Design of a Real-World, Non-Interventional Study Evaluating the Usability and Value of Integrated Digital Solutions for Routine Care of Patients with Multiple Sclerosis (P3-3.003) (2023) (0)
- How the depth of processing modulates emotional interference – evidence from EEG and pupil diameter data (2019) (0)
- Bevacizumab-induced changes in small arterial dilatation measured in vivo by dynamic retinal vessel analysis. (2010) (0)
- Demographic Patterns of MS Patients Using BRISA: An MS-Specific App in Germany (2022) (0)
- S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review (2022) (0)
- PRO45 PATIENT-REPORTED REAL-WORLD TREATMENT PATTERNS FOR CHARCOT-MARIE-TOOTH DISEASE IN THE UK AND US ASSESSED USING A DIGITAL 'BRING YOUR OWN DEVICE PLATFORM' (2019) (0)
- Long-Term Treatment With First-Line Ocrelizumab in Patients With Early RMS: 9-Year OPERA Subgroup Analysis (S46.002) (2023) (0)
- Fingolimod Observational Studies Program in Patients with Relapsing Multiple Sclerosis: Study Designs (P07.100) (2013) (0)
- P.027 Efficacy of a fourth alemtuzumab course in RRMS patients from CARE-MS II who experienced disease activity after three prior courses (2018) (0)
- Letter to the editor regarding “Therapeutic drug monitoring of natalizumab” (2020) (0)
- Response to: Kobayashi et al.: "Erythroblast appearance associated with natalizumab" Multiple Sclerosis and Related Disorders 2019. (2019) (0)
- Experimental autoimmune encephalomyelitis biomarkers indicate mechanisms mediating neurodegeneration (2007) (0)
- Limited Time from the Diabetes Patients' Perspective: Need for Conversation with the Eye Specialist (2016) (0)
- Hurdles and Barriers of Eye screening and Interdisciplinary Exchange: lessons learned from the DiabCheck study (2017) (0)
- Objective assessment of plantar flexion strength on a force plate in persons with multiple sclerosis (2022) (0)
- Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA (2017) (0)
- Relationship between Heat Intolerance and Response to Prolonged-Release Fampridine in Patients with Multiple Sclerosis (P07.078) (2012) (0)
- Physician-patient communication skills: e-tools. (2015) (0)
- [Sensory and autonomic small fiber neuropathy]. (2015) (0)
- Comparative study of microvascular function: Forearm blood flow versus dynamic retinal vessel analysis (2020) (0)
- DEFENSIVE ACTIVE COPING ASSOCIATED WITH LEFT VENTRICULAR DYSFUNCTION: THE SYMPATHETIC ACTIVITY AND AMBULATORY BLOOD PRESSURE IN AFRICAN (SABPA) STUDY: PP.38.260 (2011) (0)
- Letter to the editor to the paper: "Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis". (2018) (0)
- No correlation between lymphocyte repopulation kinetics and MS disease activity following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis (2018) (0)
- Molecular biomarkers in multiple sclerosis (2019) (0)
- Quantification of motor fatigue by Jump analysis in people with Multiple Sclerosis (2021) (0)
- Seizures after treatment with zoledronic acid for osteoporosis (2011) (0)
- P1.19 Semi-quantitative questionnaire of autonomic symptoms in patients with extrapyramidal syndromes in relation to autonomic testing (2009) (0)
- Klinischer Pfad Multiple Sklerose: Kostenaufwand für die Diagnoseabklärung „clinically isolated syndrome“ in der ambulanten Versorgung (2009) (0)
- Versorgungsstrukturelle Besonderheiten: Multiple Sklerose in Dresden und Ostsachsen (2009) (0)
- Standardisierte semiquantitative autonome Anamnese mithilfe des QAM-Systems bei Patienten mit Parkinson-Syndromen (2005) (0)
- Dimethylfumarat in der Therapie der schubförmigen MS (2014) (0)
- Entwicklung eines neurologischen, psychophysiologischen Messplatzes zur psychischen und physischen Belastungsuntersuchung, der SUEmpathy100 (2003) (0)
- Patient mit Small-Fiber-Neuropathie — das können Sie tun (2015) (0)
- Psychoneuroimmunologische Aspekte des CIS (2010) (0)
- Welchen Effekt hat das Washout bei der Umstellung von Natalizumab auf Fingolimod? (2015) (0)
- Fetale Programmierung: Die Erhöhung von Neurofilamente und MR-proANP-Werte im arteriellen Nabelschnurblut bei fetaler Wachstumsrestriktion (2022) (0)
- Fatigue und Arbeitsunfähigkeit bei erstmalig behandelten RRMS-Patienten unter Therapie mit Glatiramerazetat (2007) (0)
- Neurovegetative Funktionsstörungen bei extrapyramidalmotorischen Erkrankungen (2013) (0)
- Allgemeine und psychopathologische Belastungsfaktoren bei MS-Patienten und ihren pflegenden Angehörigen: Design und Methodik der MS Ceragiver Burden Studie (2009) (0)
- Posttranslationale Regulationsmöglichkeiten membrangebundener Enzyme am Beispiel der prostatischen 5α-Reduktase (1999) (0)
- Versorgungsstrukturelle Besonderheiten: Multiple Sklerose in der Region Hamburg (2009) (0)
- Die Anwendung von Multi-Touch-Gesten in Patientenmanagementsystemen (2013) (0)
- Versorgungsstrukturelle Besonderheiten: Multiple Sklerose im Großraum Bochum (2009) (0)
- MS-Dokumentation, -Register und -Management (2018) (0)
- PharmaNews (2020) (0)
- Regulatorische T-Zellen bei Patienten mit Multipler Sklerose (2009) (0)
- Evaluation der langfristigen klinischen und ökonomischen Auswirkungen einer Behandlung mit Ofatumumab gegenüber Dimethylfumarat und Glatirameracetat bei Patienten mit schubförmiger Multipler Sklerose aus gesellschaftlicher Sicht in Deutschland (2022) (0)
- Die dynamische Retina-Gefäßanalyse als funktioneller Parameter für die zerebrale Mikrozirkulation in Patienten mit Morbus Fabry und gesunden Probanden (2007) (0)
- Kostenanalyse neurologischer Patienten: Klinischer Pfad Multiple Sklerose (2009) (0)
- Einsatz einer standardisierten autonomen Testbatterie bei Patienten mit Parkinson-Syndromen (2005) (0)
- Multiple Sklerose: Neuroinflammation und -degeneration Hand in Hand (2020) (0)
- Kostenanalyse neurologischer Patienten (2009) (0)
- Pandysautonomie als Erstmanifestation eines Plasmozytoms (2006) (0)
- Langzeitblutdruckmessung bei Patienten mit Parkinson-Syndromen (2006) (0)
- Moderne Immuntherapie der multiplen Sklerose (2008) (0)
- Autorenverzeichnis (2022) (0)
- Etablierung eines innovativen Algorithmus zur Bestimmung der Baroreflexsensitivität – die trogonometrische regressive Spektralanalyse (2007) (0)
- Integration Touchscreen-basierter Patientenbefragung in das neurologische Dokumentationssystem MSDS (2010) (0)
- Immunologische Therapiemarker bei einer prospektiven multizentrischen Verlaufsuntersuchung über 2 Jahre bei Multiple Sklerose Patienten unter Therapie mit Glatiramerazetat (2007) (0)
- Umsetzung der Nationalen VersorgungsLeitlinie (NVL) zur Therapie des Diabetes mellitus Typ 2 in diabetologischen Schwerpunktpraxen (2017) (0)
- DAR-Studie: Dynamische Analyse retinaler Gefäße im Gesamtbild des neuro-kardiovaskulären Systems – Eine neue Methode zur Analyse der zerebralen Mikrozirkulation und Ausblick auf deren klinische Relevanz (2006) (0)
- Erratum zu: Die Generation Alpha der Digital Health Innovationen – Eine Fallstudie aus der Multiple Sklerose Versorgung (2022) (0)
- Untersuchung zur retinalen Gefäßfunktion bei gut eingestellten Typ-2-Diabetikern mittels dynamischer retinaler Gefäßanalyse (2008) (0)
- Daten sammeln aus der Praxis: der Weg zum digitalen MS-Zwilling (2021) (0)
- Kapitel 32 – Autonome Störungen (2005) (0)
- Zukunftsvisionen zur spezialisierten, interdisziplinären Versorgung von Patienten mit Autoimmunerkrankungen (2020) (0)
- eHealth-Lösungen für die MS (2022) (0)
- Multiple Sklerose: B-Zellen im Fokus von Pathophysiologie und Therapie (2020) (0)
- Die Generation Alpha der Digital Health Innovationen – Eine Fallstudie aus der Multiple Sklerose Versorgung (2022) (0)
- VAGUS 2100: Entwicklung eines Messplatzes zur Funktionsdiagnostik des autonomen Nervensystems (2002) (0)
- Neue Perspektiven eines modernen Untersuchungsverfahrens (2012) (0)
- Metabolische Störungen (2015) (0)
- Fingolimod — Sicherheitsdaten und Management in der klinischen Praxis (2013) (0)
- Blutdruckregulationsstörungen bei Patienten mit Parkinson-Syndromen (2005) (0)
- Pupillographie bei Patienten mit Parkinson-Syndromen (2006) (0)
- Variabilität und Konvergenz regionaler Versorgungsstrukturen: ein 3-Regionen Vergleich (2009) (0)
- Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Tjalf Ziemssen?
Tjalf Ziemssen is affiliated with the following schools:
